CI
The startup develops a viral oncolytic gene therapy that specifically targets and destroys cancer cells through infectious mechanisms. This approach provides clinicians with a novel treatment option for patients suffering from various types of cancer.
Updated 2 months ago
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a viral oncolytic gene therapy that specifically targets and destroys cancer cells through infectious mechanisms. This approach provides clinicians with a novel treatment option for patients suffering from various types of cancer.